Select a community
ALS including PLS and PMA
Find out more about the PatientsLikeMe
ALS Community
Home > Community Treatment Reports > Prednisone Treatment Report
What is Prednisone?

Prednisone is a synthetic corticosteroid drug that decreases inflammation and suppresses the immune system. It is used for many purposes including relapses in MS; for rheumatic disorders; neoplasms; collagen diseases. Prednisone is activated by the liver into prednisolone.

Side Effects

Side effects as an overall problem

Severe
1 25%
Moderate
0 0%
Mild
1 25%
None
2 50%

Most commonly reported side effects

Weight gain
1 25%
facial hair
1 25%
Increased appetite
1 25%
Fatigue
1 25%
  • Mild
  • Moderate
  • Severe

Dosages

  daily 5 mg daily 9 mg daily 10 mg daily 20 mg daily 25 mg daily 30 mg daily
  2 Number of Patients: 2 2 Number of Patients: 2 1 Number of Patients: 1 1 Number of Patients: 1 2 Number of Patients: 2 1 Number of Patients: 1 2 Number of Patients: 2  

Stop Reasons

Why Patients Stopped Taking Prednisone (multiple reasons could be selected)
Reason # Patients Percentage of patients
Did not seem to work
2 50% Did not seem to work: 50%
Doctor's advice
2 50% Doctor's advice: 50%
Course of treatment ended
2 50% Course of treatment ended: 50%
Side effects too severe
1 25% Side effects too severe: 25%

See all 4 patients who’ve stopped taking Prednisone

Currently Taking Prednisone

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
0
0
1
0
3

Stopped Taking Prednisone

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
2
0
0
1
1
0

Adherence, Burden & Cost See details from patient evaluations

Adherence

Taking treatment as prescribed

Always
4 100%
Usually
0 0%
Sometimes
0 0%
Never
0 0%

Burden

Difficulty being on treatment

Very
1 25%
Somewhat
0 0%
A little
0 0%
Not at all
3 75%

Cost

Paid out of pocket

$200+
0 0%
$100-199
0 0%
$50-99
0 0%
$25-49
0 0%
< $25
3 75%

See more information, including instructions, precautions, side effects, and interactions.

Report created on November 21, 2009.